PRODUCTION OF HUMANIZED MONOCLONAL ANTIBODIES AGAINST BOTULINUM TOXIN UTILIZING RECOMBINANT DNA TECHNOLOGY

PDF

Authors
  1. Mah, D.C.W.
Corporate Authors
Defence Research Establishment Suffield, Ralston ALTA (CAN);Canada West Biosciences, Calgary ALTA (CAN)
Abstract
Recent advances in recombinant antibody technology now provide a potential source of specific antibodies which is economical, stable and versatile. This report describes the cloning and characterization of murine and human recombinant antibodies using two bacteriophage antibody-cloning systems. Both murine and human recombinant antibody libraries to botulinum toxin were successfully cloned using the lambda phage ImmunoZAP system (Stratacyte, C.A.). Nine recombinant murine antibodies to botulinum toxin with possible binding activity to BoNT/A have been selected. A murine library of recombinant antibodies to BoNT/A has also been generated using the recombinant antibodies to BoNY/A has also been gbenerated using the recombinant M13 phage antibody system (Pharmacia Biotechnology, P.Q.). From a collection of 96 clones selected bt binding activity to BoNT/A, twenty-three have been well characterized and a select few will be expressed at high levels in the near future. From this collection, ten clones are being recommended for immediate DNA sequence analysis. With these accomplishments, the goals of this project are being realized and the direction of continued work on this project is clear.
Report Number
DRES-CR-94-027 — Contract Report (Final)
Date of publication
07 Apr 1994
Number of Pages
190
DSTKIM No
95-01350
CANDIS No
144714
Format(s):
Hardcopy;Document Image stored on Optical Disk

Permanent link

Document 1 of 1

Date modified: